Login to Your Account



PANEL NOTES GI SAFETY ISSUES

Merck, Alk-Abello’s ragweed tablet, Ragwitek, glides through FDA panel

By Randy Osborne
Staff Writer

Wednesday, January 29, 2014
Qualms about gastrointestinal safety and lack of data in older age groups did not deter the FDA’s Allergenic Products Advisory Committee from giving its nod to recommend approval of Ragwitek, the sublingual ragweed allergy therapy for adults from Merck & Co. Inc. and Alk-Abello A/S.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription